246 related articles for article (PubMed ID: 24902006)
1. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.
Lacouture ME; Ciccolini K; Kloos RT; Agulnik M
Thyroid; 2014 Sep; 24(9):1329-40. PubMed ID: 24902006
[TBL] [Abstract][Full Text] [Related]
2. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
3. Vandetanib and the management of advanced medullary thyroid cancer.
Campbell MJ; Seib CD; Gosnell J
Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
[TBL] [Abstract][Full Text] [Related]
4. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
6. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
[No Abstract] [Full Text] [Related]
9. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Robinson BG; Paz-Ares L; Krebs A; Vasselli J; Haddad R
J Clin Endocrinol Metab; 2010 Jun; 95(6):2664-71. PubMed ID: 20371662
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for endocrine cancer: the medullary thyroid carcinoma paradigm.
Ye L; Santarpia L; Gagel RF
Endocr Pract; 2009; 15(6):597-604. PubMed ID: 19546050
[TBL] [Abstract][Full Text] [Related]
11. Advances and controversies in the management of medullary thyroid carcinoma.
Maia AL; Wajner SM; Vargas CV
Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
[TBL] [Abstract][Full Text] [Related]
14. Vandetanib for the treatment of medullary thyroid carcinoma.
Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
[TBL] [Abstract][Full Text] [Related]
15. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
16. Kinase inhibitors for advanced medullary thyroid carcinoma.
Schlumberger M; Massicotte MH; Nascimento CL; Chougnet C; Baudin E; Leboulleux S
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):125-9. PubMed ID: 22584717
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract][Full Text] [Related]
18. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
